natgillin/translations-raw huggingface dataset:
The most frequently reported adverse reactions (occurring in ≥30% of patients) are hypertension (68.6%), diarrhoea (62.8%), decreased appetite (51.5%), weight decreased (49.1%), fatigue (45.8%), nausea (44.5%), proteinuria 36.9%), stomatitis (35.8%), vomiting (34.5%), dysphonia (34.1%), headache (34.1%), and palmar-plantar erythrodysaesthesia syndrome (PPE) (32.7%).
Neželeni učinki, o katerih najpogosteje poročajo (pojavljajo se pri ≥30 % bolnikov), so hipertenzija (68,6 %), driska (62,8 %), zmanjšan apetit (51,5 %), hujšanje (49,1 %), utrujenost (45,8 %), navzea (44,5 %), proteinurija (36,9 %), stomatitis (35,8 %), bruhanje (34,5 %), disfonija (34,1 %), glavobol (34,1 %) in sindrom palmarno-plantarne eritrodizestezije (PPE) (32,7 %).
The most frequently reported adverse reactions (≥ 5%) among abatacept-treated patients were headache, nausea, and upper respiratory tract infections.
Pri bolnikih, ki so prejemali abatacept, so najpogosteje ( 5%) poročali o glavobolu, slabosti in okužbah zgornjih dihal.
The most frequently reported adverse reactions (≥10% of patient with SLE treated with Benlysta plus standard of care and at a rate ≥1% greater than placebo) were nausea, diarrhoea, and pyrexia.
Najpogosteje zabeleženi neželeni učinki (≥ 10 % bolnikov s SLE, ki so prejemali zdravilo Benlysta in standardno oskrbo, in z deležem, ≥ 1 % večjim kot med prejemniki placeba) so bili navzea, driska in pireksija.
The most frequently reported adverse reactions after Vaxelis administration were irritability, crying, somnolence, injection site reactions (pain, erythema, swelling), pyrexia (≥38oC), decreased appetite, and vomiting.
Najpogosteje poročani neželeni učinki po cepljenju s cepivom Vaxelis so bili razdražljivost, jok, zaspanost, reakcije na mestu injiciranja (bolečina, rdečina, oteklina), povišana telesna temperatura (≥ 38 °C), zmanjšan apetit in bruhanje.
The most frequently reported adverse reactions are injection site reactions, asthenia, nausea, and increased hepatic enzymes (ALT, AST, ALP).
Najpogostejši neželeni učinki, o katerih so poročali, so reakcije na mestu injiciranja, astenija, navzea in zvišanje jetrnih encimov (ALT, AST, ALP).
The most frequently reported adverse reactions are local skin responses including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration at the application site of ingenol mebutate gel, see table 1 for MedDRA terms.
Neželeni učinki, o katerih so najpogosteje poročali, so lokalni kožni odzivi, vključno z eritemom, prhljajem/luščenjem, krastami, otekanjem, vezikulacijo/pustulacijo in erozijo/ulceracijo na mestu uporabe gela z ingenol mebutatom; glejte preglednico 1 za izraze po MedDRA.
The most frequently reported adverse reactions associated with Resolor 2mg therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain (13.7%), nausea (13.7%) and diarrhoea (12.0%)).
Najpogosteje poročani neželeni učinki, povezani z zdravljenjem z zdravilom Resolor v odmerku 2 mg, so glavobol (17,8 %) in prebavni simptomi (bolečine v trebuhu (13,7 %), navzea (13,7 %) ali diareja (12,0 %)).
The most frequently reported adverse reactions associated with SevoFlo administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
Neželeni škodljivi učinki, povezani z uporabo SevoFlo, o katerih najpogosteje poročajo, so bile hipotenzija, nato pa tahipneja, mišična napetost, razdraženost, apneja, mišične fascikulacije in bruhanje.
The most frequently reported adverse reactions associated with Sevohale administration were hypotension, followed by tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis.
Neželeni škodljivi učinki, povezani z uporabo Sevohalea, o katerih najpogosteje poročajo, so bile hipotenzija, nato pa tahipneja, mišična napetost, razdraženost, apneja, mišične fascikulacije in bruhanje.
The most frequently reported adverse reactions considered possibly or probably related to dolutegravir and abacavir/lamivudine [pooled data from 679 anti retroviral naïve subjects receiving this combination in the Phase IIb to IIIb clinical trials, see section 5.1], were nausea (12%), insomnia (7%), dizziness (6%) and headache (6%).
Med neželenimi učinki, ki so lahko ali so verjetno povezani z dolutegravirjem in abakavirjem/lamivudinom [skupni podatki 679 predhodno s protiretrovirusnimi zdravili še nezdravljenih bolnikov, ki so prejemali to kombinacijo v kliničnih preskušanjih faze IIb do IIIb, glejte poglavje 5.1], poročila najpogosteje navajajo navzeo (12%), nespečnost (7%), omotico (6%) in glavobol (6%).
The most frequently reported adverse reactions considered possibly or probably related to emtricitabine and/or tenofovir disoproxil were nausea (12%) and diarrhoea (7%) in an open-label randomised clinical study (GS-01-934, see section 5.1).
Najpogostejša neželena učinka, o katerih so poročali iz odprte, randomizirane klinične študije (GS-01- 934, glejte poglavje 5.1), in ki sta bila verjetno oziroma morda povezana z emtricitabinom in/ali dizoproksiltenofoviratom, sta bila navzea (12%) in driska (7%).
The most frequently reported adverse reactions during treatment were headache and nausea, occurring at 5 % or greater.
Najpogosteje poročana neželena učinka med zdravljenjem sta bila glavobol in navzea, ki sta se pojavila v 5 % ali več.
The most frequently reported adverse reactions during treatment were headache and nausea, occurring at 5% or greater.
Najpogosteje poročana neželena učinka med zdravljenjem sta bila glavobol in navzea, ki sta se pojavila v 5 % ali več.
The most frequently reported adverse reactions during treatment with Elonva in clinical trials (N=2,397) are pelvic discomfort (6.0%), OHSS (4.3%, see also section 4.4), headache (4.0%), pelvic pain (2.9%), nausea (2.3%), fatigue (1.5%), and breast tenderness (1.3%).
Najpogosteje poročani neželeni učinki med zdravljenjem z zdravilom Elonva v kliničnih preskušanjih (N=2.397) so bili neugodje v medenici (6,0 %), OHSS (4,3 %, glejte tudi poglavje 4.4), glavobol (4,0 %), bolečine v medenici (2,9 %), slabost (2,3 %), utrujenost (1,5 %) in občutljivost dojk (1,3 %).
The most frequently reported adverse reactions during treatment with Xultophy were hypoglycaemia and gastrointestinal adverse reactions (see section ‘Description of selected adverse reactions’ below).
Najpogosteje opisani neželeni učinki med zdravljenjem z zdravilom Xultophy so bili hipoglikemija in neželeni učinki na prebavila (glejte poglavje “Opis izbranih neželenih učinkov” v nadaljevanju).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking emtricitabine+tenofovir alafenamide in combination with elvitegravir+cobicistat were nausea (10%), diarrhoea (7%), and headache (6%).
Pri predhodno nezdravljenih bolnikih, ki so prejemali emtricitabin + alafenamidtenofovirat v kombinaciji z elvitegravirjem + kobicistatom, so bili najpogostejši neželeni učinki, o katerih so poročali v kliničnih študijah, navzea (10 %), driska (7 %) in glavobol (6 %).
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking rilpivirine hydrochloride in combination with emtricitabine+tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%).
Pri predhodno nezdravljenih bolnikih, ki so prejemali rilpivirinijev klorid v kombinaciji z emtricitabinom + dizoproksiltenofovirat fumaratom, so bili najpogostejši neželeni učinki, o katerih so poročali v kliničnih študijah, navzea (9 %), omotičnost (8 %), nenavadne sanje (8 %), glavobol (6 %), driska (5 %) in nespečnost (5 %).
The most frequently reported adverse reactions in clinical studies through 96 weeks were nausea (10%), diarrhoea (7%), and headache (6%) (pooled data from Phase 3 clinical studies GS-US-292-0104 and GS-US-292-0111 in 866 treatment-naïve adult patients receiving Genvoya).
Najpogostejši neželeni učinki v kliničnih študijah do vključno 96. tedna so bili navzea (10 %), driska (7 %) in glavobol (6 %) (združeni podatki iz kliničnih študij faze 3, GS-US-292-0104 in GS-US-292-0111 pri 866 predhodno nezdravljenih odraslih bolnikih, ki so prejemali zdravilo Genvoya).
The most frequently reported adverse reactions in SPRYCEL-treated patients with resistance or intolerance to prior imatinib therapy were fluid retention (including pleural effusion), diarrhoea, headache, nausea, skin rash, dyspnoea, haemorrhage, fatigue, musculoskeletal pain, infection, vomiting, cough, abdominal pain and pyrexia.
Neželeni učinki, o katerih so poročali najpogosteje pri bolnikih, ki so se zdravili z zdravilom SPRYCEL in se na predhodno zdravljenje z imatinibom niso odzvali ali ga niso prenašali, so bili: zastajanje tekočin (vključno s plevralnim izlivom), driska, glavobol, navzea, kožni izpuščaj, dispneja, krvavitve, utrujenost, mišično-skeletna bolečina, okužba, bruhanje, kašelj, abdominalna bolečina in zvišana telesna temperatura.
The most frequently reported adverse reactions in the ospemifene 60 mg group were hot flushes (7.5%)
Neželeni učinek, o katerem so najpogosteje poročali v skupini z ospemifenom 60 mg, so bili vročinski oblivi (7,5%).
The most frequently reported adverse reactions leading to discontinuation were infection and diarrhoea for ONIVYDE+5-FU/LV arm, and vomiting and diarrhoea for the monotherapy arm.
Najpogostejša neželena učinka, ki sta privedla do prekinitve zdravljenja, sta bila okužba in driska v veji z zdravilom ONIVYDE+5-FU/LV ter bruhanje in driska v veji z monoterapijo.
The most frequently reported adverse reactions occurring in patients receiving tedizolid phosphate in the pooled controlled Phase 3 clinical studies (tedizolid 200 mg once daily for 6 days) were nausea (6.9%), headache (3.5%), diarrhoea (3.2%) and vomiting (2.3%), and were generally mild to moderate in severity.
Najpogosteje poročani neželeni učinki v združenih nadzorovanih kliničnih študijah 3. faze pri bolnikih, ki so prejemali tedizolid fosfat (200 mg tedizolida enkrat dnevno 6 dni), so bili navzea (6,9 %), glavobol (3,5 %), diareja (3,2 %) in bruhanje (2,3%) ter so bili večinoma blagi do zmerni.
The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fatigue and headache.
Najpogosteje opisani neželeni učinki v študijah faze 2b/3 so bili navzea, driska, utrujenost in glavobol.
The most frequently reported adverse reactions related to Viramune therapy, across all clinical studies, were rash, allergic reactions, hepatitis, abnormal liver function tests, nausea, vomiting, diarrhoea, abdominal pain, fatigue, fever, headache and myalgia.
Neželene reakcije o katerih so najpogosteje poročali v povezavi z zdravljenjem z zdravilom Viramune, so bili v vseh kliničnih študijah izpuščaj, alergijske reakcije, hepatitis, nenormalni jetrni izvidi, slabost, bruhanje, driska, trebušna bolečina, utrujenost, vročina, glavobol in mialgija.
The most frequently reported adverse reactions to elvitegravir were diarrhoea (7.1%) and nausea (4.0%) (see Table 3).
Najpogostejši neželeni učinki, povezani z elvitegravirjem, so bili driska (7,1 %) in navzea (4,0 %) (glejte preglednico 3).
The most frequently reported adverse reactions to Stribild in clinical studies of virologically-suppressed patients were nausea (3% in Study
Najpogostejša neželena učinka zdravila Stribild v kliničnih študijah pri bolnikih z virusno supresijo sta bila navzea (3 % v študiji
The most frequently reported adverse reactions were bone pain (very common [ ≥ 1/10]) and musculoskeletal pain (common).
Neželena učinka, o katerih so najpogosteje poročali, sta bila bolečina v kosteh (zelo pogosto [≥ 1/10]) in mišičnoskeletna bolečina (pogosto).
The most frequently reported adverse reactions were fatigue, anaemia (see section 4.4), nausea, headache, and dysgeusia.
Neželeni učinki, o katerih so poročali najpogosteje, so bili: utrujenost, anemija (glejte poglavje 4.4), navzea, glavobol in dizgevzija.
The most frequently reported adverse reactions were fatigue, headache, pruritus, anaemia, influenza- like illness, nausea, insomnia, neutropenia, asthenia, rash, decreased appetite, dry skin, alopecia, pyrexia, myalgia, irritability, cough, diarrhoea, dyspnoea and arthralgia.
Najpogosteje poročani neželeni učinki so bili utrujenost, glavobol, srbenje, anemija, gripi podobna bolezen, navzea, nespečnost, nevtropenija, astenija, izpuščaj, zmanjšanje apetita, suha koža, alopecija, zvišana telesna temperatura, bolečina v mišicah, razdražljivost, kašelj, driska, dispneja in bolečina v sklepih.
The most frequently reported adverse reactions were injection site reactions, and hepatic enzymes increased.
Najpogosteje opisana neželena učinka sta bila: reakcije na mestu injiciranja in zvišanje jetrnih encimov.
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache ,fatigue and dizziness.
Neželeni učinki, o katerih so najpogosteje poročali, so nazofaringitis, somnolenca (zaspanost), glavobol, utrujenost in omotica.
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.
Neželeni učinki, o katerih so najpogosteje poročali, so nazofaringitis, somnolence (zaspanost), glavobol, utrujenost in omotica.
The most frequently reported adverse reactions with dexmedetomidine are hypotension, hypertension and bradycardia, occurring in approximately 25%, 15% and 13% of patients respectively.
Najpogosteje poročani neželeni učinki pri uporabi deksmedetomidina so hipotenzija, ki se pojavlja pri približno 25 % bolnikov, hipertenzija, ki se pojavlja pri približno 15 % bolnikov in bradikardija, ki se pojavlja pri približno 13 % bolnikov.
The most frequently reported adverse reactions with Incruse were nasopharyngitis and upper respiratory tract infection.
Najpogosteje poročana neželena učinka med uporabo zdravila Incruse sta bila nazofaringitis in okužba zgornjih dihal.
The most frequently reported adverse reactions with lacosamide treatment were dizziness, headache, nausea and diplopia.
Neželeni učinki, o katerih so pri zdravljenju z lakozamidom najpogosteje poročali, so bili omotica, glavobol, slabost in dvojni vid.
The most frequently reported are cleft lip, cardiovascular malformations and neural tube defect.
Prirojene okvare, o katerih najpogosteje poročajo, so zajčja ustnica, kardiovaskularne malformacije in okvare nevralne cevi.
The most frequently reported coexisting medical conditions (using a cut off of 30% or higher), in the MedDRA body systems are: Vascular disorders (73%), Cardiac disorders (46%), Gastrointestinal disorders (38%), Metabolism and nutrition disorders (40%), Renal and urinary disorders (38%), Musculoskeletal and connective tissue disorders (33%).
Najpogosteje zabeležena sočasna bolezenska stanja (z uporabo meje 30 % ali več) po organskih sistemih MedDRA so bila: žilne bolezni (73 %), bolezni srca (46 %), bolezni prebavil (38 %), presnovne in prehranske motnje (40 %), bolezni sečil (38 %), bolezni mišičnoskeletnega sistema in vezivnega tkiva (33 %).
The most frequently reported events were tachycardia (4%) and atrial fibrillation (3%) (see Section 4.4).
Najpogosteje opisana neželena učinka sta bila tahikardija (4 %) in atrijska fibrilacija (3 %) (glejte poglavje 4.4).
The most frequently reported events with abatacept (1-2%) were dizziness, headache, and hypertension.
Pri bolnikih, ki so prejemali abatacept, so najpogosteje (1-2%) poročali o omotici, glavobolu in hipertenziji.
The most frequently reported laboratory abnormality in paediatric patients receiving REYATAZ was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients.
Pri laboratorijskih meritvah so pri pediatričnih bolnikih, ki so prejemali zdravilo REYATAZ, najpogosteje poročali o povečani koncentraciji celokupnega bilirubina (≥ 2,6-krat nad zgornjo mejo referenčnih vrednosti, stopnja 3-4), in sicer pri 45% bolnikov.
The most frequently reported non-haematological effects were nausea (37 %), diarrhoea (29 %), fatigue (26 %), vomiting (24 %), alopecia (21 %) and anorexia (18 %).
Najpogosteje opisani nehematološki učinki so bili: navzea (37 %), driska (29 %), utrujenost (26 %), bruhanje (24 %), alopecija (21 %) in anoreksija (18 %).
The most frequently reported serious adverse reaction in clinical studies was syncope (0.76%).
Neželeni učinek, o katerem so v kliničnih študijah poročali najpogosteje, je sinkopa (0,76 %).
The most frequently reported serious adverse reaction was immune reconstitution syndrome.
Najpogosteje poročan resen neželeni učinek je bil sindrom imunske reaktivacije.
The most frequently reported side effects are nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness.
Neželeni učinki, o katerih so najpogosteje poročali, so nazofaringitis, somnolence (zaspanost), glavobol, utrujenost in omotica.
The most frequently reported side effects are:
Najpogostejši neželeni učinki so:
The most frequently reported side effects in studies with Invega are headache, insomnia (difficulty sleeping), sleepiness, parkinsonism (neurological symptoms including tremor and impaired muscular control), akathisia (restlessness), tachycardia (increased heart rate), dystonia (involuntary muscle contractions), tremor (shaking), upper respiratory tract infection (colds), anxiety, dizziness, increased weight, nausea, agitation, constipation, vomiting, fatigue (tiredness), depression, dyspepsia (heartburn), diarrhoea, dry mouth, toothache, muscle and bone pain, asthenia (weakness), high blood pressure, back pain, prolonged electrocardiogram QT (an alteration of the electrical activity of the heart) and cough.
Neželeni učinki, o katerih so najpogosteje poročali v študijah z zdravilom Invega, so glavobol, nespečnost (težave s spanjem), zaspanost, parkinsonizem (nevrološki simptomi, vključno s tresavico in slabšim nadzorom nad mišicami), akatizija (nemirnost), tahikardija (povišan srčni utrip), distonija (neprostovoljno krčenje mišic), tremor (tresavica), okužbe zgornjih dihalnih poti (prehladi), anksioznost, omotica, povečanje telesne mase, navzeja (slabost), vznemirjenost, zaprtje, bruhanje, utrujenost, depresija, dispepsija (zgaga), driska, suha usta, zobobol, bolečine v mišicah in kosteh, astenija (šibkost), visok krvni tlak, bolečine v hrbtu in podaljšan interval QT na elektrokardiogramu (sprememba električne dejavnosti srca) ter kašelj.
The most frequently reported side effects with Dexdor are hypotension (low blood pressure), hypertension (high blood pressure) and bradycardia (slow heart rate), occurring in approximately 25%, 15% and 13% of patients respectively.
Najpogostejši neželeni učinki, o katerih so poročali pri uporabi zdravila Dexdor, so hipotenzija (nizek krvni tlak), opažena pri okoli 25 % bolnikov, hipertenzija (visok krvni tlak), opažena pri okoli 15 % bolnikov, in bradikardija (počasen srčni utrip), opažena pri okoli 13 % bolnikov.
The most frequently reported symptoms of hypersensitivity include nausea, rash dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache.
Simptomi preobčutljivosti, o katerih so najpogosteje poročali, vključujejo navzeo, izpuščaj, dispnejo, bolečino v hrbtu, neugodje v prsih (vključno s stiskanjem v prsih), urtikarijo, bolečine v sklepih in glavobol.
The most frequently reported symptoms of hypersensitivity include nausea, rash, dyspnoea, back pain, chest discomfort (including chest tightness), urticaria, arthralgia, and headache..
Simptomi preobčutljivosti, o katerih najpogosteje poročajo, vključujejo navzeo, izpuščaj, dispnejo, bolečino v hrbtu, neugodje v prsih (vključno s stiskanjem v prsih), urtikarijo, artralgijo in glavobol.
The most frequently reported symptoms were flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea and fever or chills.
Najpogosteje opisani simptomi so zardevanje, izpuščaj s srbenjem ali brez njega, tiščanje v prsih, bolečine v hrbtu, dispneja ter povišanje telesne temperature ali mrzlica.
The most frequently used weekly dose was between 3- 5 µg/kg (25th-75th percentile respectively; median 3 µg/kg).
Najpogosteje uporabljeni tedenski odmerek je bil 3-5 µg/kg (vrednosti sta 25. in 75. percentil; mediana 3 µg/kg).
The most important serious adverse reactions identified were hepatotoxicity and thrombotic/thromboembolic events.
Najbolj pomembni resni neželeni učinki so bili hepatotoksičnost in trombotični/trombembolični dogodki.
The most important serious adverse reactions were renal failure and impairment (11.3%), arterial thromboembolisms (3.9%)*, cardiac failure (1.6%), cerebral haemorrhage (1.6%), intracranial tumour haemorrhage (0.7%)*, PRES / RPLS (0.2%)*, and hepatic failure (0.2%)* (the asterisked frequencies are from the DTC patient population).
Najpomembnejši resni neželeni učinki so bili odpoved in okvara ledvic (11,3 %), arterijske trombembolije (3,9 %)*, popuščanje srca (1,6 %), možganska krvavitev (1,6 %), krvavitev v znotrajlobanjskem tumorju (0,7 %)*, PRES / RPLS (0,2 %)* in odpoved jeter (0,2 %)*(z zvezdicami označene pogostnosti so iz skupine bolnikov z DTC).
The most important serious adverse reactions were renal failure and impairment (2.4%), arterial thromboembolisms (3.9%), cardiac failure (0.7%), intracranial tumour haemorrhage (0.7%), PRES / RPLS (0.2%), hepatic failure (0.2%), and arterial thromboembolisms (cerebrovascular accident (1.1%), transient ischaemic attack (0.7%), and myocardial infarction (0.9%).
Najpomembnejši resni neželeni učinki so bili odpoved in okvara ledvic (2,4 %), arterijska trombembolija (3,9 %), popuščanje srca (0,7 %), krvavitev v znotrajlobanjski tumor (0,7 %), PRES / RPLS (0,2 %), odpoved jeter (0,2 %) in arterijske trombembolije (cerebrovaskularni insult (1,1 %), tranzitorna ishemična ataka (0,7 %) in miokardni infarkt (0,9 %)).
The most important serious side effects are kidney failure and impairment; problems with the heart and circulation such as heart failure, blood clots in the arteries leading to stroke or heart attack; bleeding into a tumour in the brain; a syndrome known as ‘posterior reversible encephalopathy syndrome’ characterised by headache, confusion, fits and loss of vision; and liver failure.
Najpomembnejši resni neželeni učinki so odpoved in okvara ledvic, težave s srcem in ožiljem, kot so srčno popuščanje in krvni strdki v arterijah, ki lahko povzročijo možgansko ali srčno kap, krvavitev v tumor v možganih, sindrom, imenovan „sindrom posteriorne reverzibilne encefalopatije“, za katerega so značilni glavobol, zmedenost, epileptični napadi in izguba vida, ter odpoved jeter.
The most important serious side effects are kidney failure and reduced kidney function; problems with the heart and circulation such as heart failure and blood clots in the arteries leading to stroke or heart attack; bleeding in the brain or bleeding of a tumour within the skull; a syndrome known as ‘posterior reversible encephalopathy syndrome’ characterised by headache, confusion, fits and loss of vision; and liver failure.
Najpomembnejši resni neželeni učinki so odpoved ledvic in oslabljeno delovanje ledvic; težave s srcem in krvnim obtokom, kot sta srčno popuščanje in krvni strdki v arterijah, kar lahko privede do kapi ali srčnega napada; krvavitev v možganih ali krvavitev tumorja znotraj lobanje; sindrom posteriorne reverzibilne encefalopatije, za katerega so značilni glavobol, zmedenost, napadi in izguba vida; ter odpoved jeter.
The most important serious side effects seen with other pancreatic enzyme replacement medicines are ‘anaphylactic shock’ and fibrosing colonopathy.
Najpomembnejša resna neželena učinka, o katerih so poročali pri uporabi drugih zdravil z encimi trebušne slinavke, sta »anafilaktični šok« in fibrozirajoča kolonopatija.
The most increased serious adverse events were diarrhoea in patients treated with Vectibix in combination with either FOLFOX or FOLFIRI, and dehydration and pulmonary embolism when patients were treated with Vectibix in combination with FOLFIRI.
Pri bolnikih, ki so prejemali zdravilo Vectibix v kombinaciji s FOLFOX ali s FOLFIRI, se je najbolj povečala pojavnost resnega neželenega učinka diareje, pri bolnikih, ki so prejemali zdravilo Vectibix v kombinaciji s FOLFIRI pa dehidracija in pljučna embolija.